Long survival with metronomic therapy for heavily pretreated advanced gastric cancer: case report

Abstract
A 79-year-old patient with metastatic gastric cancer who failed with two previous lines of chemotherapy for the last 9 months received third-line chemotherapy with oral cyclophosphamide. This has resulted in an extraordinary long-term progression-free survival of 11 months. Toxicity has been low and well tolerated. Oral cyclophosphamide seems to be potentially active agent for salvage chemotherapy in gastric carcinoma patients who failed with prior lines of chemotherapy.

Keywords: gastric, cancer, metastatic, oral cyclophosphamide

Introduction
We present an interesting case of disease control under metronomic chemotherapy for heavily pretreated metastatic gastric cancer.

Case report
A 79-year-old man with complaint of abdominal pain was diagnosed with an advanced gastric cancer in December 2009. The patient had no significant co morbidities. Upper GI endoscopy revealed a mass in gastric antrum. The biopsy was in favor of well differentiated adenocarcinoma. The total body computed tomography (CT) showed multiple liver metastasis and abdominal lymph nodes in addition to a gastric mass. The performance status was good (PS=1). The patient was, also, screened using G8 scale and the score was good (15/17). Routine Palliative chemotherapy was indicated. The patient received irinotecan (240mg/m² on day 1) plus capecitabine (1800mg/m² for 14days) this protocol was repeated every 3 weeks. The treatment was well tolerated. Only grade 1 diarrhea was occurred. The evaluation by CT scan after the third cycle showed a stable disease according the Recist criteria. Unfortunately, after the sixth cycle the disease was progressive especially in the liver.

According the new data concerning the anti-HER therapy in gastric cancer, the testing of HER was done. The patient received as second line treatment consisting in association between trastuzumab (Monoclonal antibody targeting the HER protein) and fluoropyrimidin based chemotherapy is the gold standard treatment for advanced gastric cancer with over expression of HER. Some authors discussed also the anti-angiogenic of metronomic therapy. Based on these informations we decided to administer the patient irinotecan, paclitaxel or docetaxel are a treatment options. In second line for fit patient, irinotecan, paclitaxel or docetaxel are a treatment options. The antiangiogenic targeted therapies are promising. Two of them the ramucirumab and alatinib showed a survival benefit in refractory metastatic gastric cancer.

In August 2011, according the fact that the performance status was still good, the patient received oral cyclophosphamide (50mg per day for 20days in 30days cycle). The evaluation by CT scan was done every 3 months. The disease was stable for 11 months. During this chemotherapy, no significant side-effects were observed. After this period, the liver metastasis and abdominal lymph nodes grown quickly and the patient died from his disease.

Discussion
Metastatic gastric cancer remains an incurable disease, with median overall survival less than 12 months in general. Since the publication of Toga study, the association between trastuzumab (Monoclonal antibody targeting the HER protein) and fluoropyrimidin based chemotherapy is the gold standard treatment for advanced gastric cancer with over expression of HER. The second line for fit patient, irinotecan, paclitaxel or docetaxel are a treatment options. The antiangiogenic targeted therapies are promising. Two of them the ramucirumab and alatinib showed a survival benefit in refractory metastatic gastric cancer. In our context in 2013, patients with metastatic gastric cancer who failed with two previous lines of chemotherapy but this point remains controversial.

The therapeutic concept of administering agents continuously at lower doses is known as “metronomic therapy” (MT). Several studies have shown that low-dose cyclophosphamide had an immune stimulatory effect by the induction of dendritic cell maturation and the increase in tumor associated NK cells and macrophages. Some authors discussed also the anti-angiogenic of metronomic chemotherapy but this point remains controversial. For our patient, oral cyclophosphamide permitted tumor control for at approximatively 11 months. No serious adverse events occurred. To the best of our knowledge, no published reports have reported the efficacy of cyclophosphamide in gastric cancer.

Conclusion
This case report constitutes a potentially important window, indicating a potential role for the metronomic therapy in the treatment of heavily pretreated gastric cancer.

Acknowledgements
None.

Conflict of interest
The author declares no conflict of interest.
Long survival with metronomic therapy for heavily pretreated advanced gastric cancer: case report


References


